Safety and effectiveness of a novel dual-energy radiofrequency/pulsed field ablation catheter: 12-month results of the FlexPulse study
Europace · 04.11.2026 · 28 (11)
DOI: 10.1093/europace/euag238 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Europace, online erschienen am 28.08.2026. Verfasst von Ayman A Hussein und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Pacing and Electrophysiology, Department of Cardiovascular Medicine/J2-2, Cleveland Clinic, J2-2 9500 Euclid Avenue, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation, Cardiac Catheters. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Abbott.
Abstract (Originalsprache)
Aims
Pulsed field (PF) ablation is increasingly used to treat paroxysmal atrial fibrillation (PAF). FlexPulse (NCT06676072) was conducted to evaluate safety and effectiveness of a novel dual-energy, flexible-tip focal ablation catheter with radiofrequency and PF for treatment of symptomatic, drug-refractory PAF. Methods and results FlexPulse was a global, prospective, single-arm, multicentre study. The ablation procedures targeted pulmonary vein isolation (PVI) and adjunctive ablation at operators’ discretion. The primary safety endpoint was occurrence of pre-defined safety events within 7 days of any ablation procedure. The primary effectiveness endpoint was freedom from a composite of recurrent AF/atrial tachycardia/atrial flutter, repeat procedure, new use or escalation of class I/III AAD, and/or cardioversion through 12-months. Overall, 180 subjects underwent PAF ablation. Successful PVI was achieved in all participants. Additional non-PV ablations were performed in 37.2% (67/180) of subjects. The primary safety endpoint event rate was 1.7%. The primary effectiveness endpoint was 74.6% at 12 months, and freedom from documented AF/AFL/AT recurrence was 77.4% (92.6% without weekly transtelephonic monitoring). In 15 subjects who underwent repeat ablation after the blanking period, remapping indicated that 79.7% (47/59) of the PVs were durably isolated from the index procedures. Retrospective analysis found that workflows with PFA Index (PI) ≥ 30 and AutoMark distance up to 6 mm target had a 12-month freedom from AF/AFL/AT of 84.6%.
Conclusion
In this trial, ablation with TactiFlex Duo in patients with symptomatic, drug-refractory PAF was safe and effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiac Pacing and Electrophysiology, Department of Cardiovascular Medicine/J2-2, Cleveland Clinic, J2-2 9500 Euclid Avenue, Cleveland, OH 44195, USA.
- Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- Department of Cardiovascular Medicine, South Denver Cardiology, Denver, CO, USA.
- Department of Cardiovascular Medicine, Duke University, Durham, NC, USA.
- II. Internal Medicine Department, NO Landesgesundheitsagentur, Wiener Neustadt, Austria.
- Department of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
ORCID-Profile: Ayman A Hussein, Gediminas Rackauskas, Sri Sundaram, Jonathan P Piccini, Jose Osorio, Dhanunjaya R Lakkireddy, Matthew C Hyman, Laura Zitella Verbick, Nick Dirckx, Virginia Woods, Monica Lo
Förderung
- Abbott
Zitieren
APA
Hussein, A. A., Rackauskas, G., Sundaram, S., Piccini, J. P., Roithinger, F. X., Tung, P., Osorio, J., Colley, B. J., Siddiqui, U. R., Lakkireddy, D. R., Chinitz, L. A., Hyman, M. C., Zitella Verbick, L., Dirckx, N., Woods, V., Lo, M., & FlexPulse Investigators (2026). Safety and effectiveness of a novel dual-energy radiofrequency/pulsed field ablation catheter: 12-month results of the FlexPulse study. Europace, 28(11). https://doi.org/10.1093/europace/euag238
Vancouver
Hussein AA, Rackauskas G, Sundaram S, Piccini JP, Roithinger FX, Tung P, et al. Safety and effectiveness of a novel dual-energy radiofrequency/pulsed field ablation catheter: 12-month results of the FlexPulse study. Europace. 2026;28(11). doi:10.1093/europace/euag238
BibTeX
@article{Hussein2026,
author = {Hussein, Ayman A and Rackauskas, Gediminas and Sundaram, Sri and Piccini, Jonathan P and Roithinger, Franz Xaver and Tung, Patricia and Osorio, Jose and Colley, B Judson and Siddiqui, Usman R and Lakkireddy, Dhanunjaya R and Chinitz, Larry A and Hyman, Matthew C and Zitella Verbick, Laura and Dirckx, Nick and Woods, Virginia and Lo, Monica and FlexPulse Investigators, FlexPulse Investigators},
title = {Safety and effectiveness of a novel dual-energy radiofrequency/pulsed field ablation catheter: 12-month results of the FlexPulse study},
journal = {Europace},
year = {2026},
volume = {28},
number = {11},
doi = {10.1093/europace/euag238}
}
EUVIMED